✦ LIBER ✦

Donor Bone Marrow Infusion in Renal Transplantation

✍ Scribed by G. Ciancio; R. Garcia-Morales; G.W. Burke; D. Roth; V. Esquenazi; A. Rosen; C. Ricordi; A. Tzakis; J. Miller

Book ID: 117236124
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 123 KB
Volume: 30
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(98)00276-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Donor bone marrow infusion in cadaveric

Donor bone marrow infusion in cadaveric renal transplantation

✍ G Ciancio 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Donor bone marrow infusions are toleroge

Donor bone marrow infusions are tolerogenic in human renal transplantation

✍ G Ciancio; R Garcia-Morales; J Mathew; M Carreno; G.W Burke; C Ricordi; N Kenyon 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Donor-specific bone marrow infusion afte

Donor-specific bone marrow infusion after orthotopic liver transplantation

✍ K. Rolles; A.K. Burroughs; B.R. Davidson; H.G. Prentice; M.D. Hamon 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 481 KB

Effects of donor bone marrow infusion in

Effects of donor bone marrow infusion in clinical lung transplantation

✍ Si M Pham; Abdul S Rao; Adriana Zeevi; Kenneth R McCurry; Robert J Keenan; J.Dav 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 282 KB

Perioperative donor bone marrow infusion

Perioperative donor bone marrow infusion in cadaver kidney transplant recipients

✍ R.O. Garcia-Morales; G. Ciancio; J. Mathew; Y. Jin; A. Rosen; C. Ricordi; G.W. B 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Immunomodulatory effects of donor lympho

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation

✍ Robert J. Soiffer; Edwin P. Alyea; Jerome Ritz 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 546 KB

Recently, donor lymphocyte infusions have been successfully used to treat patients with CML who have relapsed following allogeneic bone marrow transplantation (BMT). Responses can be achieved in more than 6&70% of patients with stable phase CML without the need for the additional high dose cytotoxic